VAERS Explorer
Back to explore

Report #2825509

Received Feb 10, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
—
Recovered
Unknown
Vaccinated
—
Onset
—
Days to onset
—
Hospital days
—

Vaccines (2)

TypeNameManufacturerDoseLotRoute / Site
DTAPDTAP (NO BRAND NAME)UNKNOWN MANUFACTURERUNK—OT
UNKVACCINE NOT SPECIFIED (NO BRAND NAME)UNKNOWN MANUFACTURERUNK3CA03C3OT

Symptoms (1)

Wrong product administered

Symptom narrative

inappropriate use due to inadvertently administered Dtap instead of Tdap with no reported adverse event; Initial information received on 03-Feb-2025 regarding an unsolicited valid non-serious case received from a nurse. This case involves an unknown age and unknown gender patient who experienced inappropriate use due to inadvertently administered Diphtheria-15/Tetanus/5 AC Pertussis Vaccine instead of Diphtheria, Tetanus And Acellular Pertussis Vaccine [tdap] with no reported adverse event. On an unknown date, the patient received an unknown dose of suspect Diphtheria-15/Tetanus/5 AC Pertussis Vaccine, suspension for injection, lot number: 3CA03C3, expiry date not reported was inadvertently administered dtap instead of received a unknown dose of suspect Diphtheria, Tetanus And Acellular Pertussis Vaccine (tdap) produced by unknown manufacturer lot number not reported via unknown route in unknown administration site both for Immunization. tdap with no reported adverse event (wrong product administered) (latency:same day). Reportedly,Relayed the information to the school nurse which they got a little upset because they just want to make sure the student will not receive an extra dose of what was already given to them.. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.